0000000000395896

AUTHOR

D. Hoppe

showing 6 related works from this author

Abstract of the 68th Meeting (Spring Meeting) 6–9 March 1990, Heidelberg

1990

0303 health sciencesPhysiologyChemistryClinical BiochemistryTibialis AnteriorHuman physiology030204 cardiovascular system & hematologyPharmacologySpring (mathematics)ArticleAtrial Natriuretic Peptide03 medical and health sciences0302 clinical medicineAtrial natriuretic peptidePhysiology (medical)Spreading DepressionCapsaicinExtensor Digitorum Longus030304 developmental biologyPflugers Archiv
researchProduct

CCDC 639296: Experimental Crystal Structure Determination

2007

Related Article: J.Becker, R.Frohlich, K.Salorinne, D.Hoppe|2007|Eur.J.Org.Chem.|2007|3337|doi:10.1002/ejoc.200700219

Space GroupCrystallography(1R3S3(1R5R)3aR7aS)-3-(66-Dimethylbicyclo(3.1.1)hept-2-en-2-yl)-1-(naphthalen-2-yl)-hexahydroisobenzofuran-4(1H)-oneCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Supplementary Material for: Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves’ Orbitopat…

2020

Objectives: To investigate the predictive factors for changes in the quality of life (GO-QoL) of patients with Graves’ orbitopathy (GO) prior to and after specific treatment. Methods: A prospective follow-up study was conducted at an academic tertiary referral orbital center with a joint thyroid-eye clinic on 100 consecutive patients with GO. Before and after the standard 12-week course of weekly intravenous methylprednisolone (cumulative dose 4.5 g), the GO-QoL questionnaire provided by the European Group on Graves’ Orbitopathy (EUGOGO) was completed. Endocrine and ophthalmic assessments were performed at each visit. Results: All patients were biochemically euthyroid and untreated for GO a…

researchProduct

CCDC 639295: Experimental Crystal Structure Determination

2007

Related Article: J.Becker, R.Frohlich, K.Salorinne, D.Hoppe|2007|Eur.J.Org.Chem.|2007|3337|doi:10.1002/ejoc.200700219

Space GroupCrystallographyCrystal System(1S3R3(1R5R)3aS7aR)-3-(66-Dimethylbicyclo(3.1.1)hept-2-en-2-yl)-1-(naphthalen-2-yl)-hexahydroisobenzofuran-4(1H)-oneCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 639294: Experimental Crystal Structure Determination

2007

Related Article: J.Becker, R.Frohlich, K.Salorinne, D.Hoppe|2007|Eur.J.Org.Chem.|2007|3337|doi:10.1002/ejoc.200700219

Space GroupCrystallographyCrystal SystemCrystal Structure(1R3S3aR7aS)-1-(4-Bromophenyl)-3-(t-butyl)-hexahydroisobenzofuran-4(1H)-oneCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 639293: Experimental Crystal Structure Determination

2007

Related Article: J.Becker, R.Frohlich, K.Salorinne, D.Hoppe|2007|Eur.J.Org.Chem.|2007|3337|doi:10.1002/ejoc.200700219

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parametersent-(3S3(1R))-3-(1-(4-Bromophenyl)-1-hydroxymethyl)cyclohex-1-enyl NN-di-isopropylcarbamateExperimental 3D Coordinates
researchProduct